6K9 Stock Overview
A biopharmaceutical company, develops products for the treatment of solid tumors.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Context Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.06 |
| 52 Week High | US$2.28 |
| 52 Week Low | US$0.69 |
| Beta | 2.3 |
| 11 Month Change | 13.19% |
| 3 Month Change | 33.77% |
| 1 Year Change | 100.00% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -63.26% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6K9 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 3.0% | 0.8% | 1.9% |
| 1Y | 100.0% | -20.0% | -0.8% |
Return vs Industry: 6K9 exceeded the German Pharmaceuticals industry which returned -20% over the past year.
Return vs Market: 6K9 exceeded the German Market which returned -0.8% over the past year.
Price Volatility
| 6K9 volatility | |
|---|---|
| 6K9 Average Weekly Movement | 10.4% |
| Pharmaceuticals Industry Average Movement | 5.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 6K9's share price has been volatile over the past 3 months.
Volatility Over Time: 6K9's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 5 | Martin Lehr | www.contexttherapeutics.com |
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.
Context Therapeutics Inc. Fundamentals Summary
| 6K9 fundamental statistics | |
|---|---|
| Market cap | €164.10m |
| Earnings (TTM) | -€17.00m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-9.7x
P/E RatioIs 6K9 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6K9 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$18.57m |
| Earnings | -US$18.57m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.25 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 6K9 perform over the long term?
See historical performance and comparison